Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Regorafenib enhances antitumor immune efficacy of anti-PD-L1 immunotherapy on oral squamous cell carcinoma.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie - 1 Mar 2022

Chiang I-Tsang, Lee Yuan-Hao, Tan Zhao-Lin, Hsu Fei-Ting, Tu Hsi-Feng

Abstract excerpt

Oral squamous cells carcinoma (OSCC) is the most common oral malignancy that majorly originated from oral cavity. Though the prognostic and predictive value of targeting checkpoint molecules has been reported on OSCC, the treatment efficacy of monotherapy is remaining limited. Several studies suggested that multikinase inhibitors may show potential to facilitate anti-PD-L1-induced anti-tumor immunity....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Carcinoma, Squamous Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Survival

Share to Immune Checkpoint Inhibitors

Share to Macrophages

Share to Mouth Neoplasms

Share to Phenylurea Compounds

Share to Pyridines

Source

Identifiers

PMID: 35092865
DOI: 10.1016/j.biopha.2022.112661

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Regorafenib enhances antitumor immune efficacy of anti-PD-L1 immunotherapy on oral squamous cell carcinoma.PMID 35092865Read ↗

Protein kinase D3 regulates the expression of the immunosuppressive protein, PD‑L1, through STAT1/STAT3 signalingSemantic proximity Read ↗

PD-L1 expression, tumor-infiltrating lymphocytes, mismatch repair deficiency, EGFR alteration and HPV infection in sinonasal squamous cell carcinoma.Semantic proximity Read ↗

Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages.Semantic proximity Read ↗

Modulating Tumor-Associated Macrophages through CSF1R Inhibition: A Potential Therapeutic Strategy for HNSCCSemantic proximity Read ↗

Expansion of CD4+ cytotoxic T lymphocytes with specific gene expression patterns may contribute to suppression of tumor immunity in oral squamous cell carcinoma: single-cell analysis and in vitro experimentsSemantic proximity Read ↗

EMT, angiogenesis, and cell-cycle pathways are significantly impacted in oral cancer patients, among whom a large fraction may potentially respond to immune checkpoint therapySemantic proximity Read ↗

Combination strategies with PD-1/PD-L1 blockade: current advances and future directionsSemantic proximity Read ↗

Role of tumour-associated macrophages in oral squamous cells carcinoma progression: an update on current knowledge.Semantic proximity Read ↗

SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.Semantic proximity Read ↗

PXDN as a pan-cancer biomarker and promotes tumor progress via immune inhibition in nasopharyngeal carcinomaSemantic proximity Read ↗

IRAK2, an IL1R/TLR Immune Mediator, Enhances Radiosensitivity via Modulating Caspase 8/3-Mediated Apoptosis in Oral Squamous Cell CarcinomaSemantic proximity Read ↗

CD103 blockade impair anti-CTLA-4 immunotherapy in oral cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.